Clinical Trial: NCT05595447
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
Status:
RECRUITINGPhase:
Phase 2| Lead Sponsor: | Hospital Regional de Alta Especialidad del Bajio |
| Information Provided By: | Hospital Regional de Alta Especialidad del Bajio |
| Last Update Posted: | 2025-03-12 |
Study Overview
Brief Summary
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT.
What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade
1?
Official Title
Conditions
Intervention / Treatment
- Drug: Brentuximab Vedotin 50 MG [Adcetris]
Other Study ID Numbers
- CI/HRAEB/038/2022
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | Hospital Regional de Alta Especialidad del Bajio |
| Information Provided By: | Hospital Regional de Alta Especialidad del Bajio |
| Last Update Posted: | 2025-03-12 |
Study Overview
Brief Summary
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT.
What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade
1?
Official Title
Conditions
Intervention / Treatment
- Drug: Brentuximab Vedotin 50 MG [Adcetris]
Other Study ID Numbers
- CI/HRAEB/038/2022